Infectious Viral Shedding of SARS-CoV-2 Delta Following Vaccination: A Longitudinal Cohort Study

The impact of vaccination on SARS-CoV-2 infectiousness is not well understood. We compared longitudinal viral shedding dynamics in unvaccinated and fully vaccinated adults. SARS-CoV-2-infected adults were enrolled within 5 days of symptom onset and nasal specimens were self-collected daily for two weeks and intermittently for an additional two weeks. SARS-CoV-2 RNA load and infectious virus were analyzed relative to symptom onset stratified by vaccination status. We tested 1080 nasal specimens from 52 unvaccinated adults enrolled in the pre-Delta period and 32 fully vaccinated adults with predominantly Delta infections. While we observed no differences by vaccination status in maximum RNA levels, maximum infectious titers and the median duration of viral RNA shedding, the rate of decay from the maximum RNA load was faster among vaccinated; maximum infectious titers and maximum RNA levels were highly correlated. Furthermore, amongst participants with infectious virus, median duration of infectious virus detection was reduced from 7.5 days (IQR: 6.0-9.0) in unvaccinated participants to 6 days (IQR: 5.0-8.0) in those vaccinated (P = 0.02). Accordingly, the odds of shedding infectious virus from days 6 to 12 post-onset were lower among vaccinated participants than unvaccinated participants (OR 0.42 95% CI 0.19-0.89). These results indicate that vaccination had reduced the probability of shedding infectious virus after 5 days from symptom onset.

Citing Articles

Risk period for transmission of SARS-CoV-2 and seasonal influenza: a rapid review.

Stone E, Okasako-Schmucker D, Taliano J, Schaefer M, Kuhar D Infect Control Hosp Epidemiol. 2025; :1-9.

PMID: 39989317 PMC: 11883656. DOI: 10.1017/ice.2025.11.

Does the COVID-19 Vaccination Reduce the Risk to Transmit SARS-CoV-2 to Others?.

Kampf G Adv Exp Med Biol. 2024; 1457:247-264.

PMID: 39283431 DOI: 10.1007/978-3-031-61939-7_14.

Early biological markers of post-acute sequelae of SARS-CoV-2 infection.

Lu S, Peluso M, Glidden D, Davidson M, Lugtu K, Pineda-Ramirez J Nat Commun. 2024; 15(1):7466.

PMID: 39198441 PMC: 11358427. DOI: 10.1038/s41467-024-51893-7.

SARS-CoV-2 Polymerase Chain Reaction Cycle Threshold Trends in Patients Who Are Immunocompromised and Implications for Isolation Precautions.

Harris C, Vaidya V, Lan Z, Klompas M, Rhee C, Baden L Open Forum Infect Dis. 2024; 11(7):ofae367.

PMID: 39077053 PMC: 11285146. DOI: 10.1093/ofid/ofae367.

Deisolation in the Healthcare Setting Following Recent COVID-19 Infection.

Baumgart S, McLachlan A, Kenny H, McKew G, Maddocks S, Chen S Viruses. 2024; 16(7).

PMID: 39066294 PMC: 11281359. DOI: 10.3390/v16071131.

References

Salvatore P, Lee C, Sleweon S, McCormick D, Nicolae L, Knipe K . Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta variant in a federal prison, July-August 2021. Vaccine. 2022; 41(11):1808-1818. PMC: 9744684. DOI: 10.1016/j.vaccine.2022.11.045. View

Wang Y, Chen R, Hu F, Lan Y, Yang Z, Zhan C . Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China. EClinicalMedicine. 2021; 40:101129. PMC: 8435265. DOI: 10.1016/j.eclinm.2021.101129. View

Bouton T, Atarere J, Turcinovic J, Seitz S, Sher-Jan C, Gilbert M . Viral Dynamics of Omicron and Delta Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants With Implications for Timing of Release from Isolation: A Longitudinal Cohort Study. Clin Infect Dis. 2022; 76(3):e227-e233. PMC: 9278204. DOI: 10.1093/cid/ciac510. View

Pulliam J, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome M . Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science. 2022; 376(6593):eabn4947. PMC: 8995029. DOI: 10.1126/science.abn4947. View

Puhach O, Adea K, Hulo N, Sattonnet P, Genecand C, Iten A . Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2. Nat Med. 2022; 28(7):1491-1500. DOI: 10.1038/s41591-022-01816-0. View

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C . Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. N Engl J Med. 2021; 385(16):1474-1484. PMC: 8362591. DOI: 10.1056/NEJMoa2109072. View

Ovsyannikova I, Haralambieva I, Crooke S, Poland G, Kennedy R . The role of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility and severity. Immunol Rev. 2020; 296(1):205-219. PMC: 7404857. DOI: 10.1111/imr.12897. View

van Kampen J, van de Vijver D, Fraaij P, Haagmans B, Lamers M, Okba N . Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). Nat Commun. 2021; 12(1):267. PMC: 7801729. DOI: 10.1038/s41467-020-20568-4. View

10.

Accorsi E, Britton A, Fleming-Dutra K, Smith Z, Shang N, Derado G . Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA. 2022; 327(7):639-651. PMC: 8848203. DOI: 10.1001/jama.2022.0470. View

11.

Hsu L, Grune B, Buess M, Joisten C, Klobucnik J, Niessen J . COVID-19 Breakthrough Infections and Transmission Risk: Real-World Data Analyses from Germany's Largest Public Health Department (Cologne). Vaccines (Basel). 2021; 9(11). PMC: 8624814. DOI: 10.3390/vaccines9111267. View

12.

Tregoning J, Flight K, Higham S, Wang Z, Pierce B . Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021; 21(10):626-636. PMC: 8351583. DOI: 10.1038/s41577-021-00592-1. View

13.

Servellita V, Morris M, Sotomayor-Gonzalez A, Gliwa A, Torres E, Brazer N . Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California. Nat Microbiol. 2022; 7(2):277-288. DOI: 10.1038/s41564-021-01041-4. View

14.

Kelly J, Lu S, Anglin K, Garcia-Knight M, Pineda-Ramirez J, Goldberg S . Magnitude and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Household Transmission: A Longitudinal Cohort Study. Clin Infect Dis. 2022; 75(Suppl 2):S193-S204. PMC: 9278251. DOI: 10.1093/cid/ciac545. View

15.

Singanayagam A, Hakki S, Dunning J, Madon K, Crone M, Koycheva A . Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis. 2021; 22(2):183-195. PMC: 8554486. DOI: 10.1016/S1473-3099(21)00648-4. View

16.

Prunas O, Warren J, Crawford F, Gazit S, Patalon T, Weinberger D . Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel. Science. 2022; 375(6585):1151-1154. PMC: 9261115. DOI: 10.1126/science.abl4292. View

17.

Collie S, Champion J, Moultrie H, Bekker L, Gray G . Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. N Engl J Med. 2021; 386(5):494-496. PMC: 8757569. DOI: 10.1056/NEJMc2119270. View

18.

Matsuyama S, Nao N, Shirato K, Kawase M, Saito S, Takayama I . Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci U S A. 2020; 117(13):7001-7003. PMC: 7132130. DOI: 10.1073/pnas.2002589117. View

19.

Chia P, Ong S, Chiew C, Ang L, Chavatte J, Mak T . Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study. Clin Microbiol Infect. 2021; 28(4):612.e1-612.e7. PMC: 8608661. DOI: 10.1016/j.cmi.2021.11.010. View

20.

Kustin T, Harel N, Finkel U, Perchik S, Harari S, Tahor M . Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med. 2021; 27(8):1379-1384. PMC: 8363499. DOI: 10.1038/s41591-021-01413-7. View